Shattuck Labs (NASDAQ:STTK) Posts Earnings Results, Beats Estimates By $0.01 EPS

Shattuck Labs (NASDAQ:STTK) issued its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01, Zacks reports. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $1.06 on Friday. The firm’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.49. Shattuck Labs has a one year low of $0.94 and a one year high of $11.76. The firm has a market cap of $50.37 million, a PE ratio of -0.69 and a beta of 1.66.

Wall Street Analyst Weigh In

STTK has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “neutral” rating on shares of Shattuck Labs in a research report on Thursday. Leerink Partners assumed coverage on Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 price objective on the stock. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a research report on Monday, March 17th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a research report on Thursday. Four investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.